ZYDUS GETS DGCI NOD FOR HU­MAN TRI­ALS OF VACCINE

The Asian Age - - Financial -

New Delhi, July 3: Zydus, a part of the Cadila Health­care group, on Fri­day said its in­dige­nously de­vel­oped Covid-19 vaccine can­di­date— ZyCoV-D—has suc­cess­fully com­pleted pre-clin­i­cal phase and has re­ceived per­mis­sion from au­thor­i­ties to con­duct hu­man tri­als.

"Zydus has already man­u­fac­tured clin­i­cal good man­u­fac­tur­ing prac­tice (GMP) batches of the vaccine can­di­date and plans to ini­ti­ate the clin­i­cal tri­als in July 2020 across mul­ti­ple sites in In­dia in over 1,000 sub­jects," the com­pany said.

ZyCoV-D, de­vel­oped at the com­pany's Vaccine Tech­nol­ogy Cen­tre in Ahmed­abad, has now re­ceived per­mis­sion from the Drug Con­troller Gen­eral of In­dia (DGCI) Cen­tral Drugs Stan­dard Con­trol Or­gan­i­sa­tion (CDSCO) to ini­ti­ate phase I/II hu­man clin­i­cal tri­als in In­dia, Cadila Health­care said in a reg­u­la­tory fil­ing.

—PTI

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.